vlog

[Skip to Navigation]
Sign In
Original Investigation
January 3, 2024

Home-Use Transcranial Direct Current Stimulation for the Treatment of a Major Depressive Episode: A Randomized Clinical Trial

Author Affiliations
  • 1Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil
  • 2Laboratory of Neuroscience and National Institute of Biomarkers in Psychiatry, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil
  • 3Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany
  • 4Charlotte Fresenius Hochschule, Munich, Germany
  • 5Department of Internal Medicine, University of São Paulo Medical School, São Paulo, Brazil
  • 6Center for Clinical and Epidemiological Research, Hospital Universitário, University of São Paulo, São Paulo, Brazil
  • 7Department of Head and Skin, Psychiatry and Medical Psychology, Ghent University Hospital, Ghent University, Ghent, Belgium
  • 8Ghent Experimental Psychiatry Laboratory, Ghent, Belgium
  • 9Laboratory of Neuromodulation and Center for Clinical Research Learning, Physics, and Rehabilitation Department, Spaulding Rehabilitation Hospital, Boston, Massachusetts
JAMA Psychiatry. 2024;81(4):329-337. doi:10.1001/jamapsychiatry.2023.4948
Key Points

Question What is the efficacy of fully unsupervised home-use transcranial direct current stimulation (tDCS) combined with either a digital psychological intervention or digital placebo for the treatment of a major depressive episode?

Findings In this randomized clinical trial including 210 adults with a major depressive episode, no statistically significant differences were detected between home-use tDCS combined with either a digital psychological intervention or digital placebo vs sham in reducing depressive symptoms after 6 weeks.

Meaning The findings indicate that unsupervised home use tDCS should not be currently recommended in clinical practice.

Abstract

Importance Transcranial direct current stimulation (tDCS) is moderately effective for depression when applied by trained staff. It is not known whether self-applied tDCS, combined or not with a digital psychological intervention, is also effective.

Objective To determine whether fully unsupervised home-use tDCS, combined with a digital psychological intervention or digital placebo, is effective for a major depressive episode.

Design, Setting, and Participants This was a double-blinded, sham-controlled, randomized clinical trial with 3 arms: (1) home-use tDCS plus a digital psychological intervention (double active); (2) home-use tDCS plus digital placebo (tDCS only), and (3) sham home-use tDCS plus digital placebo (double sham). The study was conducted between April 2021 and October 2022 at participants’ homes and at Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil. Included participants were aged 18 to 59 years with major depression and a Hamilton Depression Rating Scale, 17-item version (HDRS-17), score above 16, a minimum of 8 years of education, and access to a smartphone and internet at home. Exclusion criteria were other psychiatric disorders, except for anxiety; neurologic or clinical disorders; and tDCS contraindications.

Interventions tDCS was administered in 2-mA, 30-minute prefrontal sessions for 15 consecutive weekdays (1-mA, 90-second duration for sham) and twice-weekly sessions for 3 weeks. The digital intervention consisted of 46 sessions based on behavioral therapy. Digital placebo was internet browsing.

Main Outcomes and Measures Change in HDRS-17 score at week 6.

Results Of 837 volunteers screened, 210 participants were enrolled (180 [86%] female; mean [SD] age, 38.9 [9.3] years) and allocated to double active (n = 64), tDCS only (n = 73), or double sham (n = 73). Of the 210 participants enrolled, 199 finished the trial. Linear mixed-effects models did not reveal statistically significant group differences in treatment by time interactions for HDRS-17 scores, and the estimated effect sizes between groups were as follows: double active vs tDCS only (Cohen d, 0.05; 95% CI, −0.48 to 0.58; P = .86), double active vs double sham (Cohen d, −0.20; 95% CI, −0.73 to 0.34; P = .47), and tDCS only vs double sham (Cohen d, −0.25; 95% CI, −0.76 to 0.27; P = .35). Skin redness and heat or burning sensations were more frequent in the double active and tDCS only groups. One nonfatal suicide attempt occurred in the tDCS only group.

Conclusions and Relevance Unsupervised home-use tDCS combined with a digital psychological intervention or digital placebo was not found to be superior to sham for treatment of a major depressive episode in this trial.

Trial Registration ClinicalTrials.gov Identifier:

Add or change institution
2 Comments for this article
EXPAND ALL
Challenging the Efficacy and Safety of Home-Based Transcranial Direct Current Stimulation in MDD Management
Dr Om Prakash, M.D. (Psychiatry) | Professor of Psychiatry, Institute of Human Behaviour and Allied Sciences (IHBAS), New Delhi
Challenging the Efficacy and Safety of Home-Based Transcranial Direct Current Stimulation in MDD Management

To the Editor of JAMA Psychiatry,
The pivotal role of transcranial direct current stimulation (tDCS) in treating Major Depressive Disorder (MDD), particularly in non-clinical settings [1], necessitates a critical examination. The promising implications of tDCS, as shown in recent studies such as Burkhardt et al. (2023) [2] bring forth a paradigm shift in MDD treatment, emphasizing its potential when used alongside conventional therapies like SSRIs. However, this progression also beckons caution, especially considering the home-based application of tDCS.
The complexity of MDD, characterized by intricate
neurological and psychological dynamics, demands precise and supervised therapeutic interventions. The application of tDCS in a non-clinical environment [1] raises concerns regarding the adequate management of treatment parameters and patient safety. The lack of professional oversight in home settings can lead to improper usage, risking inefficacy and potential exacerbation of depressive symptoms, or even precipitating suicidality [3]. These risks underscore the necessity of stringent guidelines and expert monitoring when considering tDCS as a viable treatment option.
Furthermore, while acknowledging the strides made in neuromodulation therapies, it is imperative to reflect on the established, time-tested treatments like Electroconvulsive Therapy (ECT). ECT continues to be a cornerstone in managing severe depression cases, particularly those involving suicidality, as endorsed by the American Psychiatric Association's guidelines [4]. The evolving landscape of depression treatment should not overshadow the efficacy and relevance of such traditional modalities.
The individual response to tDCS, as investigated in a study published in JAMA Psychiatry (2022) [5] adds another layer of complexity. Factors such as age, gender, and specific depressive symptomatology significantly influence treatment outcomes. This individual variability necessitates the development of personalized treatment plans, overseen by mental health professionals, to optimize therapeutic efficacy and minimize risks. Moreover, a 2021 meta-analysis in the American Journal of Psychiatry [6] reviews tDCS outcomes across various mental health conditions. The findings indicate benefits but also highlight response variability, underscoring the need for more extensive research to establish clear, evidence-based guidelines for tDCS application in clinical practice.
In conclusion, while tDCS presents as a promising and evolving therapeutic tool in MDD treatment, its application outside the clinical setting raises substantial concerns regarding efficacy and safety. The current body of literature emphasizes the critical need for a holistic treatment approach, integrating both innovative and traditional therapies. This approach should prioritize patient safety, treatment efficacy, and the complexities inherent in managing MDD. As mental health professionals, our overarching aim should be to navigate these complexities with an informed, cautious, and patient-centric approach.
Om Prakash, M.D.

References:
1. Borrione L, Cavendish BA, Aparicio LVM, et al. Home-Use Transcranial Direct Current Stimulation for the Treatment of a Major Depressive Episode: A Randomized Clinical Trial. JAMA Psychiatry. Published online January 03, 2024. doi:10.1001/jamapsychiatry.2023.4948
2. Burkhardt G, Kumpf U, Crispin A, et al. Transcranial direct current stimulation as an additional treatment to s
CONFLICT OF INTEREST: None Reported
READ MORE
Correction
andre brunoni, MD, PhD | Faculdade de Medicina da Universidade de Sao Paulo
On behalf of all coauthors of this recently published article in JAMA Psychiatry “Home-Use Transcranial Direct Current Stimulation for the Treatment of a Major Depressive Episode: A Randomized Clinical Trial”, by Borrione et al. we regret to inform that we accidentally excluded 2 coauthors during the revision and publication process. Their names were introduced as co-authors of the article, in its revised version.
CONFLICT OF INTEREST: None Reported
×